Register for our free email digests:
Division of Teva Pharmaceutical Industries Ltd.
Latest From KuDOS Pharmaceuticals Ltd.
Five and a half years after its decision to spin off its pharmaceutical business and a year and a half away from having the US Supreme Court break its monopoly on BRCA gene testing, Myriad Genetics is no longer an exception among molecular diagnostics companies. It must find its way along a more crowded path.
Singapore’s MerLion Completes Phase III Finafloxacin Studies For Outer Ear Infection, Looks Ahead To Other Indications
Singapore-based MerLIon Pharmaceuticals has reached another milestone with its finafloxacin antibiotic with the topic form for outer ear infection successfully passing Phase III trials in North America. But the firm is still looking for help taking another indication into Phase III.
By licensing MK-1775 from Merck, AstraZeneca underscores the key strategic role DNA damage response will play in the U.K. drug maker’s attempts to build oncology into a growth engine.
Financings Of The Fortnight Sees New Biotech Funding All Over The Globe, And Without Much VC Participation
Plus news on recent financial activity by Merrimack, Promethera, ADC Therapeutics and Enterome Bioscience.
- Specialty Pharmaceuticals
- Therapeutic Areas
- Neurology, Nervous System
- North America
- Company Type
- 1st Tier Biotech
- Parent & Subsidiaries
Teva Pharmaceutical Industries Ltd.
- Anesta Corp.
- BioAssets Development Corp.
- Cell Therapeutics (UK) Ltd.
- Cephalon Australia
- Ception Therapeutics Inc.
- ChemGenex Pharmaceuticals Ltd.
- CIMA Labs Inc.
- Gemin X Pharmaceuticals Inc.
- Groupe Lafon
- Mepha LLC
- PolaRx Biopharmaceuticals Inc.
- Salmedix Inc.
- Zeneus Pharma Ltd.
- Cephalon Inc.
- Senior Management
J. Kevin Buchi, CEO
Wilco Groenhuysen, EVP & CFO
Jeffrey Vaught, PhD, EVP, CSO
- Contact Info
Phone: (610) 344-0200
41 Moores Rd.
Frazer, PA 19355
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.